Stay ahead in the rapidly evolving LNP space with the 4 th LNP Formulation & Process Development Summit—the largest global meeting dedicated purely to LNPs. The official event guide is your must-have ...

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

Lipid nanoparticle (LNP) vehicles have been crucial to the success of the Pfizer-BioNTech and Moderna COVID-19 vaccines. Without these LNP vehicles, the vaccines’ mRNA payloads wouldn’t have survived ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process requiring a high degree of expertise, capabilities, and experience. The development and manufacturing ...

The success of mRNA vaccines has sparked significant interest and investment in using mRNA technology to treat a broad range of diseases, including cancer, infectious diseases, and rare conditions.

The success of the mRNA-LNP COVID-19 vaccines have clinically proven the modality of lipid-based nanoparticle delivery, demonstrating the possibilities for rapid design, development, and manufacturing ...

CHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSINESS WIRE)--BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service ...